Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260099 | 0.86 | AGTR2 (0.39) | AGTR1AGTR2CYP3A4ADORA3ADRA2B | |
| SCHEMBL28664828 | 0.83 | AGTR2 (0.49) | AGTR1AGTR2PPARGLTB4R2 | |
| SCHEMBL30539277 | 0.83 | AGTR2 (0.49) | AGTR1AGTR2PPARGLTB4R2 | |
| SCHEMBL31554980 | 0.83 | ABCB11 (0.63) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL30539225 | 0.83 | AGTR2 (0.49) | AGTR1AGTR2PPARGLTB4R2 | |
| SCHEMBL9199697 | 0.80 | — | — | |
| SCHEMBL7006258 | 0.80 | ABCB11 (0.47) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL9197386 | 0.80 | ABCB11 (0.56) | AGTR1AGTR2ABCB11EGFRERBB2 | |
| SCHEMBL22175723 | 0.80 | — | — | |
| SCHEMBL9638344 | 0.79 | ABCB11 (0.56) | AGTR1AGTR2ABCB11EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182994-A1 | Crystal of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-07-31 | — | — | US | disclosed |
| US-20060205801-A1 | Crystal and process for producing the same | HASHIMOTO HIDEO | 2006-09-14 | — | — | US | disclosed |
| US-7067546-B2 | Crystal and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040215023-A1 | Crystal and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1420016-A1 | CRYSTAL AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205801-A1 | Crystal and process for producing the same | RCC1, RCC2, NPM1 | AGTR1 1565/4885AGTR2 2260/4885ABCB11 919/4885 |
| US-20080182994-A1 | Crystal of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid and process for producing the same | BRD7, BMI1, ALK | AGTR1 1868/4885AGTR2 2143/4885ABCB11 1249/4885 |
| US-20040215023-A1 | Crystal and process for producing the same | SBDS, RCC1, RCC2 | AGTR1 1545/4885AGTR2 1976/4885ABCB11 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.